Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG1068 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Currently treated with SSRI | EXPERIMENTAL | - |
| Not currently treated with SSRI | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RG1068 (synthetic human secretin) | DRUG | Single-dose, IV infusion |
Inclusion Criteria: * History of pancreatitis * Medically stable * Able to give informed consent Exclusion Criteria: * Prior history of pancreatic resection * Prior history of pancreatic duct drainage procedure * Presence of a pancreatic stent * Unstable cardiovascular disease * Any contraindicat...
RG1068 is an investigational synthetic human secretin being studied for use in autism, pancreatitis, and obsessive compulsive disorder (OCD). It is a small molecule developed by Repligen Corporation. Clinical trials have evaluated it in children with autism, in patients with OCD, and in subjects with pancreatic abnormalities.
RG1068 is being developed by Repligen Corporation, a biopharmaceutical company traded on NASDAQ under the ticker RGEN. The company has sponsored clinical trials of RG1068 in the United States across multiple indications.
RG1068 has completed Phase 3 clinical trials for autism and pancreatitis, and a Phase 2 trial for obsessive compulsive disorder. All trials are completed, and the drug remains investigational, meaning it is not yet approved by regulatory authorities.
RG1068 has been studied in three completed trials: NCT00036244, a Phase 3 study in children with autism; NCT00216294, a Phase 2 safety study in patients with OCD; and NCT00660335, a Phase 3 safety and efficacy study in subjects with pancreatic abnormalities.
RG1068 is a synthetic form of human secretin, a naturally occurring hormone. It is being investigated as a therapeutic agent for conditions such as autism and pancreatitis, and as a diagnostic enhancer for magnetic resonance cholangiopancreatography (MRCP) in pancreatic disease.